Volume 22: Issue 1 (Apr 2023): Disorders of Divalent Ions, Renal Bone Disease and Nephrolithiasis

Narisawa S, Huang L, Iwasaki A, Hasegawa H, Alpers DH, Millán JL: Accelerated fat absorption in intestinal alkaline phosphatase knockout mice. Mol Cell Biol 23: 7525–7530, 2003 PubMed

Narisawa S, Huang L, Iwasaki A, Hasegawa H, Alpers DH, Millán JL: Accelerated fat absorption in intestinal alkaline phosphatase knockout mice. Mol Cell Biol 23: 7525–7530, 2003 PubMed)| false
• Search Google Scholar
• Export Citation

Haarhaus M, Brandenburg V, Kalantar-Zadeh K, Stenvinkel P, Magnusson P: Alkaline phosphatase: A novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol 13: 429–442, 2017 PubMed

Haarhaus M, Brandenburg V, Kalantar-Zadeh K, Stenvinkel P, Magnusson P: Alkaline phosphatase: A novel treatment target for cardiovascular disease in CKD. Nat Rev Nephrol 13: 429–442, 2017 PubMed)| false
• Search Google Scholar
• Export Citation

Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7: 1–59 201 2017

Kidney Disease: Improving Global Outcomes CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7: 1–59 201 2017)| false
• Search Google Scholar
• Export Citation

Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al.: Diversity of the human intestinal microbial flora. Science 308: 1635–1638, 2005 PubMed

Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al.: Diversity of the human intestinal microbial flora. Science 308: 1635–1638, 2005 PubMed)| false
• Search Google Scholar
• Export Citation

Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al.: What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7: 14, 2019 PubMed

Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al.: What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7: 14, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Haenen D, Zhang J, Souza da Silva C, Bosch G, van der Meer IM, van Arkel J, et al.: A diet high in resistant starch modulates microbiota composition, SCFA concentrations, and gene expression in pig intestine. J Nutr 143: 274–283, 2013 PubMed

Haenen D, Zhang J, Souza da Silva C, Bosch G, van der Meer IM, van Arkel J, et al.: A diet high in resistant starch modulates microbiota composition, SCFA concentrations, and gene expression in pig intestine. J Nutr 143: 274–283, 2013 PubMed)| false
• Search Google Scholar
• Export Citation

Peng L, He Z, Chen W, Holzman IR, Lin J: Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 61: 37–41, 2007 PubMed

Peng L, He Z, Chen W, Holzman IR, Lin J: Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 61: 37–41, 2007 PubMed)| false
• Search Google Scholar
• Export Citation

Bergman EN: Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 70: 567–590, 1990 PubMed

Bergman EN: Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev 70: 567–590, 1990 PubMed)| false
• Search Google Scholar
• Export Citation

Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al.: Gut microbiota functions: Metabolism of nutrients and other food components. Eur J Nutr 57: 1–24, 2018 PubMed

Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al.: Gut microbiota functions: Metabolism of nutrients and other food components. Eur J Nutr 57: 1–24, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI: Human nutrition, the gut microbiome and the immune system. Nature 474: 327–336, 2011 PubMed

Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI: Human nutrition, the gut microbiome and the immune system. Nature 474: 327–336, 2011 PubMed)| false
• Search Google Scholar
• Export Citation

Meijers B, Evenepoel P, Anders HJ: Intestinal microbiome and fitness in kidney disease. Nat Rev Nephrol 15: 531–545, 2019 PubMed

Meijers B, Evenepoel P, Anders HJ: Intestinal microbiome and fitness in kidney disease. Nat Rev Nephrol 15: 531–545, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Kieffer DA, Piccolo BD, Vaziri ND, Liu S, Lau WL, Khazaeli M, et al.: Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am J Physiol Renal Physiol 310: F857–F871, 2016 PubMed

Kieffer DA, Piccolo BD, Vaziri ND, Liu S, Lau WL, Khazaeli M, et al.: Resistant starch alters gut microbiome and metabolomic profiles concurrent with amelioration of chronic kidney disease in rats. Am J Physiol Renal Physiol 310: F857–F871, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, et al.: Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun 10: 1835, 2019 PubMed

Kikuchi K, Saigusa D, Kanemitsu Y, Matsumoto Y, Thanai P, Suzuki N, et al.: Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun 10: 1835, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl (114): S12–S19, 2009 PubMed

Evenepoel P, Meijers BK, Bammens BR, Verbeke K: Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl (114): S12–S19, 2009 PubMed)| false
• Search Google Scholar
• Export Citation

Uzawa T, Hori M, Ejiri S, Ozawa H: Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone 16: 477–484, 1995 PubMed

Uzawa T, Hori M, Ejiri S, Ozawa H: Comparison of the effects of intermittent and continuous administration of human parathyroid hormone(1-34) on rat bone. Bone 16: 477–484, 1995 PubMed)| false
• Search Google Scholar
• Export Citation

Saini V, Marengi DA, Barry KJ, Fulzele KS, Heiden E, Liu X, et al.: Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem 288: 20122–20134, 2013 PubMed

Saini V, Marengi DA, Barry KJ, Fulzele KS, Heiden E, Liu X, et al.: Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH. J Biol Chem 288: 20122–20134, 2013 PubMed)| false
• Search Google Scholar
• Export Citation

Yu M, D’Amelio P, Tyagi AM, Vaccaro C, Li JY, Hsu E, et al.: Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent PTH-induced bone anabolism in mice. EMBO Rep 19: 156–171, 2018 PubMed

Yu M, D’Amelio P, Tyagi AM, Vaccaro C, Li JY, Hsu E, et al.: Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent PTH-induced bone anabolism in mice. EMBO Rep 19: 156–171, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, Galley S, et al.: T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 10: 229–240, 2009 PubMed

Terauchi M, Li JY, Bedi B, Baek KH, Tawfeek H, Galley S, et al.: T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab 10: 229–240, 2009 PubMed)| false
• Search Google Scholar
• Export Citation

Li JY, Yu M, Pal S, Tyagi AM, Dar H, Adams J, et al.: Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota. J Clin Invest 130: 1767–1781, 2020 PubMed

Li JY, Yu M, Pal S, Tyagi AM, Dar H, Adams J, et al.: Parathyroid hormone-dependent bone formation requires butyrate production by intestinal microbiota. J Clin Invest 130: 1767–1781, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al.: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341: 569–573, 2013 PubMed

Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al.: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341: 569–573, 2013 PubMed)| false
• Search Google Scholar
• Export Citation

Zeng H, Chi H: Metabolic control of regulatory T cell development and function. Trends Immunol 36: 3–12, 2015 PubMed

Zeng H, Chi H: Metabolic control of regulatory T cell development and function. Trends Immunol 36: 3–12, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al.: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 446–450, 2013 PubMed

Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al.: Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504: 446–450, 2013 PubMed)| false
• Search Google Scholar
• Export Citation

Massy ZA, Drueke TB: Gut microbiota orchestrates PTH action in bone: Role of butyrate and T cells. Kidney Int 98: 269–272, 2020 PubMed

Massy ZA, Drueke TB: Gut microbiota orchestrates PTH action in bone: Role of butyrate and T cells. Kidney Int 98: 269–272, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Yu M, Malik Tyagi A, Li JY, Adams J, Denning TL, Weitzmann MN, et al.: PTH induces bone loss via microbial-dependent expansion of intestinal TNF+ T cells and Th17 cells. Nat Commun 11: 468, 2020 PubMed

Yu M, Malik Tyagi A, Li JY, Adams J, Denning TL, Weitzmann MN, et al.: PTH induces bone loss via microbial-dependent expansion of intestinal TNF⁺ T cells and Th17 cells. Nat Commun 11: 468, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Tawfeek H, Bedi B, Li JY, Adams J, Kobayashi T, Weitzmann MN, et al.: Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One 5: e12290, 2010 PubMed

Tawfeek H, Bedi B, Li JY, Adams J, Kobayashi T, Weitzmann MN, et al.: Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss. PLoS One 5: e12290, 2010 PubMed)| false
• Search Google Scholar
• Export Citation

Miossec P, Korn T, Kuchroo VK: Interleukin-17 and type 17 helper T cells. N Engl J Med 361: 888–898, 2009 PubMed

Miossec P, Korn T, Kuchroo VK: Interleukin-17 and type 17 helper T cells. N Engl J Med 361: 888–898, 2009 PubMed)| false
• Search Google Scholar
• Export Citation

Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al.: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673–2682, 2006 PubMed

Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al.: Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673–2682, 2006 PubMed)| false
• Search Google Scholar
• Export Citation

Uluçkan Ö, Jimenez M, Karbach S, Jeschke A, Graña O, Keller J, et al.: Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med 8: 330ra37, 2016 PubMed

Uluçkan Ö, Jimenez M, Karbach S, Jeschke A, Graña O, Keller J, et al.: Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts. Sci Transl Med 8: 330ra37, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al.: Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139: 485–498, 2009 PubMed

Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al.: Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139: 485–498, 2009 PubMed)| false
• Search Google Scholar
• Export Citation

Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al.: Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167: 1125–1136.e8, 2016 PubMed

Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, et al.: Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167: 1125–1136.e8, 2016 PubMed)| false
• Search Google Scholar
• Export Citation

Yang Y, Torchinsky MB, Gobert M, Xiong H, Xu M, Linehan JL, et al.: Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 510: 152–156, 2014 PubMed

Yang Y, Torchinsky MB, Gobert M, Xiong H, Xu M, Linehan JL, et al.: Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 510: 152–156, 2014 PubMed)| false
• Search Google Scholar
• Export Citation

Lioufas NM, Pascoe EM, Hawley CM, Elder GJ, Badve SV, Block GA, et al.: Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol 33: 59–76, 2022 PubMed

Lioufas NM, Pascoe EM, Hawley CM, Elder GJ, Badve SV, Block GA, et al.: Systematic review and meta-analyses of the effects of phosphate-lowering agents in nondialysis CKD. J Am Soc Nephrol 33: 59–76, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, et al.; IMPROVE-CKD Trial Investigators: A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol 31: 2653–2666, 2020 PubMed

Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, et al.; IMPROVE-CKD Trial Investigators: A randomized trial on the effect of phosphate reduction on vascular end points in CKD (IMPROVE-CKD). J Am Soc Nephrol 31: 2653–2666, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al.: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407–1415, 2012 PubMed

Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al.: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407–1415, 2012 PubMed)| false
• Search Google Scholar
• Export Citation

Segawa H, Kaneko I, Yamanaka S, Ito M, Kuwahata M, Inoue Y, et al.: Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am J Physiol Renal Physiol 287: F39–F47, 2004 PubMed

Segawa H, Kaneko I, Yamanaka S, Ito M, Kuwahata M, Inoue Y, et al.: Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am J Physiol Renal Physiol 287: F39–F47, 2004 PubMed)| false
• Search Google Scholar
• Export Citation

Ketteler M, Wiecek A, Rosenkranz AR, Pasch A, Rekowski J, Hellmann B, et al.: Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis–A randomized clinical trial. Kidney Int Rep 6: 594–604, 2020 PubMed

Ketteler M, Wiecek A, Rosenkranz AR, Pasch A, Rekowski J, Hellmann B, et al.: Efficacy and safety of a novel nicotinamide modified-release formulation in the treatment of refractory hyperphosphatemia in patients receiving hemodialysis–A randomized clinical trial. Kidney Int Rep 6: 594–604, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Ogawa T, Shimada M, Nagano N, Ito K, Ando T, Shimomura Y, et al.: Oral administration of Bifidobacterium longum in a gastro-resistant seamless capsule decreases serum phosphate levels in patients receiving haemodialysis. Clin Kidney J 5: 373–374, 2012 PubMed

Ogawa T, Shimada M, Nagano N, Ito K, Ando T, Shimomura Y, et al.: Oral administration of Bifidobacterium longum in a gastro-resistant seamless capsule decreases serum phosphate levels in patients receiving haemodialysis. Clin Kidney J 5: 373–374, 2012 PubMed)| false
• Search Google Scholar
• Export Citation

Fusaro M, Cozzolino M, Plebani M, Iervasi G, Ketteler M, Gallieni M, et al.: Sevelamer use, vitamin K levels, vascular calcifications, and vertebral fractures in hemodialysis patients: Results from the VIKI Study. J Bone Miner Res 36: 500–509, 2021 PubMed

Fusaro M, Cozzolino M, Plebani M, Iervasi G, Ketteler M, Gallieni M, et al.: Sevelamer use, vitamin K levels, vascular calcifications, and vertebral fractures in hemodialysis patients: Results from the VIKI Study. J Bone Miner Res 36: 500–509, 2021 PubMed)| false
• Search Google Scholar
• Export Citation

Wu PH, Liu PY, Chiu YW, Hung WC, Lin YT, Lin TY, et al.: Comparative gut microbiome differences between ferric citrate and calcium carbonate phosphate binders in patients with end-stage kidney disease. Microorganisms 8: 2040, 2020 PubMed

Wu PH, Liu PY, Chiu YW, Hung WC, Lin YT, Lin TY, et al.: Comparative gut microbiome differences between ferric citrate and calcium carbonate phosphate binders in patients with end-stage kidney disease. Microorganisms 8: 2040, 2020 PubMed)| false
• Search Google Scholar
• Export Citation

Miao YY, Xu CM, Xia M, Zhu HQ, Chen YQ: Relationship between gut microbiota and phosphorus metabolism in hemodialysis patients: A preliminary exploration. Chin Med J (Engl) 131: 2792–2799, 2018 PubMed

Miao YY, Xu CM, Xia M, Zhu HQ, Chen YQ: Relationship between gut microbiota and phosphorus metabolism in hemodialysis patients: A preliminary exploration. Chin Med J (Engl) 131: 2792–2799, 2018 PubMed)| false
• Search Google Scholar
• Export Citation

Bennis Y, Cluet Y, Titeca-Beauport D, El Esper N, Ureña P, Bodeau S, et al.: The effect of sevelamer on serum levels of gut-derived uremic toxins: Results from in vitro experiments and a multicenter, double-blind, placebo-controlled, randomized clinical trial. Toxins (Basel) 11: 279, 2019 PubMed

Bennis Y, Cluet Y, Titeca-Beauport D, El Esper N, Ureña P, Bodeau S, et al.: The effect of sevelamer on serum levels of gut-derived uremic toxins: Results from in vitro experiments and a multicenter, double-blind, placebo-controlled, randomized clinical trial. Toxins (Basel) 11: 279, 2019 PubMed)| false
• Search Google Scholar
• Export Citation

Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V, Thiele I: Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front Genet 6: 148, 2015 PubMed

Magnúsdóttir S, Ravcheev D, de Crécy-Lagard V, Thiele I: Systematic genome assessment of B-vitamin biosynthesis suggests co-operation among gut microbes. Front Genet 6: 148, 2015 PubMed)| false
• Search Google Scholar
• Export Citation

Bellone F, Cinquegrani M, Nicotera R, Carullo N, Casarella A, Presta P, et al.: Role of vitamin K in chronic kidney disease: A focus on bone and cardiovascular health. Int J Mol Sci 23: 5282, 2022 PubMed

Bellone F, Cinquegrani M, Nicotera R, Carullo N, Casarella A, Presta P, et al.: Role of vitamin K in chronic kidney disease: A focus on bone and cardiovascular health. Int J Mol Sci 23: 5282, 2022 PubMed)| false
• Search Google Scholar
• Export Citation

Frick PG, Riedler G, Brögli H: Dose response and minimal daily requirement for vitamin K in man. J Appl Physiol 23: 387–389, 1967 PubMed

Frick PG, Riedler G, Brögli H: Dose response and minimal daily requirement for vitamin K in man. J Appl Physiol 23: 387–389, 1967 PubMed)| false
• Search Google Scholar
• Export Citation

Fusaro M, Noale M, Viola V, Galli F, Tripepi G, Vajente N, et al.; VItamin K Italian (VIKI) Dialysis Study Investigators: Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. J Bone Miner Res 27: 2271–2278, 2012 PubMed

Fusaro M, Noale M, Viola V, Galli F, Tripepi G, Vajente N, et al.; VItamin K Italian (VIKI) Dialysis Study Investigators: Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. J Bone Miner Res 27: 2271–2278, 2012 PubMed)| false
• Search Google Scholar
• Export Citation

Saritas T, Reinartz S, Krüger T, Ketteler M, Liangos O, Labriola L, et al.; Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: The VitaVasK randomized controlled trial. Clin Kidney J 15: 2300–2311, 2022

Saritas T, Reinartz S, Krüger T, Ketteler M, Liangos O, Labriola L, et al.; Vitamin K1 and progression of cardiovascular calcifications in hemodialysis patients: The VitaVasK randomized controlled trial. Clin Kidney J 15: 2300–2311, 2022)| false
• Search Google Scholar
• Export Citation

Holden RM, Booth SL, Zimmerman D, Moist L, Norman P, Day AG, et al.: Inhibit progression of coronary artery calcification with vitamin k in hemodialysis patients (the iPACK-HD study): A randomized, placebo-controlled multi-centre, pilot trial. Nephrol Dial Transplant 38: 746–756, 2023 PubMed

Holden RM, Booth SL, Zimmerman D, Moist L, Norman P, Day AG, et al.: Inhibit progression of coronary artery calcification with vitamin k in hemodialysis patients (the iPACK-HD study): A randomized, placebo-controlled multi-centre, pilot trial. Nephrol Dial Transplant 38: 746–756, 2023 PubMed)| false
• Search Google Scholar
• Export Citation